← Back to Clinical Trials
Recruiting Phase 3 NCT06500234

Nutrition Impact on Immunotherapy of Cancer

Trial Parameters

Condition Nutrition Disorders
Sponsor Qingdao Central Hospital
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 300
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2024-06-01
Completion 2025-05-31
Interventions
Megestrol Acetate and olanzapineStarch powder 50 mg

Brief Summary

This study investigates nutritional status and outcomes of immuntherapy in cancer patients.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of cancer, malnutrition Age \>18 years Performance status ECOG of 0 or 2. Life expectancy ≥ 6 months. At least one lesion measurable as defined by standard imaging criteria for the patient's tumor type (RECIST v1.1) Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment Postmenopausal or evidence of non-childbearing status for women of childbearing potential Patient is willing and able to comply with the protocol for the duration of the study. For all oral medications patients must be able to comfortably swallow capsules; Exclusion Criteria: * Patients unable to swallow orally administered medication and patients with Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs History of allogenic organ, bone marrow or double umbilical cord blood transplantation. Active or prior documented autoimmune or inflammatory disorders Unc

Related Trials